Thalidomide revisited: pharmacology and clinical applications

Bibliography

• MELLIN GW, KATZENSTEIN M: The saga of thalidomide. Neuropathy to embyropathy, with case reports of con-genital anomalies. New Engl. J. Med. (1962) 267:1184–1193.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of cases of teratogenicity and events that led to thalidomide's withdrawal from the marketplace.
   Google Scholar
• STIRLING D, SHERMAN M, STRAUSS S: Thalidomide. Asurprising recovery. J. Am. Pharm. Assoc. (1997) NS37:306–313.
   Google Scholar
• SOMERS GF: Pharmacological properties of thalido-mide (a-phthalimido glutarimide), a new sedative hypnotic drug. Br. J. Pharmacol. (1960) 15:111–116.
   PubMed Web of Science ®Google Scholar
• MELLIN G, KATZENSTEIN M: The saga of thalidomide(concluded). New Engl. J. Med. (1962) 267:1238–1244.
   PubMed Web of Science ®Google Scholar
• •Part two of the review by these authors cited above.
   Google Scholar
• SHESKIN J: Thalidomide in the treatment of lepra reac- tions. Clin. Pharmacol. Ther. (1965) 6:303–306.
   PubMed Web of Science ®Google Scholar
• •Original report of the discovery of thalidomide's efficacy in ENL.
   Google Scholar
• KOCH HP: Thalidomide and congeners as anti- inflammatory agents. Prog. Med. Chem. (1985) 22:165–242.
   PubMedGoogle Scholar
• •Detailed discussion of thalidomide in clinical use.
   Google Scholar
• ERIKSSON T, BJORKMAN S, ROTH B, FYGE A, HOGLUNDP: Stereospeciflc determination, chiral inversion in vi-tro and pharmacokinetics in humans of the enanti-omers of thalidomide. Chirality (1995) 7:44–52.
   PubMed Web of Science ®Google Scholar
• TSENG S, PAK G, WASHENIK K, POMERANZ MK, SHU-PACK JL: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. (1996) 35:969–979.
   PubMed Web of Science ®Google Scholar
• ••Review covering diseases for which thalidomide has beenfound effective, the clinical adverse events associated with thalidomide therapy and the mechanism of action of the drug.
   Google Scholar
• CHEN T-L, VOGELSANG GB, PETTY BG et al.: Plasma pharmacokinetics and urinary excretion of thalido-mide after oral dosing in healthy male volunteers. Drug Metab. Dispos. Biol. (1989) 17:402–405.
   PubMed Web of Science ®Google Scholar
• •Study exploring pharmacokinetics of thalidomide in a healthy population.
   Google Scholar
• SCHUMACHER H, SMITH RL, WILLIAMS RT: The metabo- lism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. (1965) 25:338–351.
   PubMed Web of Science ®Google Scholar
• FAURE M, THIVOLET J, GAUCHERAND M: Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch. Der-matol. Res. (1980) 269:275–280.
   Web of Science ®Google Scholar
• BARNHILL RL, DOLL NJ, MILLMAN LE et al: Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J. Am. Acad. Dermatol. (1984) 11:814–819.
   PubMed Web of Science ®Google Scholar
• GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface mole-cules involved in the adhesion cascade. Immunophar-macology (1996) 31:213–221.
   PubMed Web of Science ®Google Scholar
• MCHUGH SM, RIFKIN IR, DEIGHTON J et al.: The immu-nosuppressive drug thalidomide induces T helper cell type 2 ('1h2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated hu-man peripheral blood mononuclear cell cultures. Clin. Exp. Immunol (1995) 99:160–167.
   PubMed Web of Science ®Google Scholar
• GAD SM, SHANNON EJ, KROTOSKI WA et al.: Thalido-mide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr. Rev. (1985) 56:35–39.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R et al.: Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A et al: Tha-lidomide exerts its inhibitory action on tumor necro-sis factor a by enhancing mRNA degradation. J. Exp. Med. (1993) 177:1675–1680.
   PubMed Web of Science ®Google Scholar
• KLAUSNER JD, FREEDMAN VH, KAPLAN G: Thalidomide as an anti-TNF-a inhibitor: implications for clinical use. Clin. Immunol Immunopathol (1996) 81:219–223.
   PubMedGoogle Scholar
• ••Clear explanation of the effect of thalidomide on TNF-a andclinical evidence supporting the role of TNF-a in the patho-genesis of tuberculosis and HIV infections.
   Google Scholar
• SAMPAIO EP, MOREIRA AL, SARNO EN, MALTA AM, KAPLAN G: Prolonged treatment with recombinant in-terferon induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. (1992) 175:1729–1737.
   PubMed Web of Science ®Google Scholar
• SARNO EN, GRAU GE, VIEIRA LMM, NERY JA: Serum lev-els of tumor necrosis factor-a and interleukin-16 dur-ing leprosy reactional states. Clin. Exp. Immunol (1991) 84:103–108.
   PubMed Web of Science ®Google Scholar
• •Early evidence for the role of TNF-a in erythema lupus nodosum.
   Google Scholar
• SAMPAIO EP, KAPLAN G, MIRANDA A et al.: The influ-ence of thalidomide on the clinical and immunologi-cal manifestation of erythema nodosum leprosum. J. Infect. Dis. (1993) 168:408–414.
   PubMed Web of Science ®Google Scholar
• TAVARES JL, WANGOO A, DILWORTH P et al.: Thalido-mide reduces tumour necrosis factor-a production by human alveolar macrophages. Respir. Med. (1997) 91:31–39.
   PubMed Web of Science ®Google Scholar
• MOREIRA A, WANG J, TSENOVA L, NORTH R, KAPLAN G:The effect of thalidomide on the cellular immune re-sponse to mycobacteria infection in mice. J. Cell. Bio-chem. (1995) 57(Suppl. 19B):88. Abstract.
   Google Scholar
• DAVIDSEN SK, SUMMERS JB: Inhibitors of TNEcc synthe-sis. Exp. Opin. Ther. Patents (1995) 5:1087–1100.
   Google Scholar
• STRIETER RM, KUNKEL SJ, BONE RC: Role of tumor ne-crosis factor-alpha in disease states and inflammation. Grit. Care Med. (1993) 21:S447–S463.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Clinical applications of research on angio-genesis. New Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• ••Thorough discussion of clinical applications of anti-angiogenic agents.
   Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Tha- lidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• ••Initial research suggesting that thalidomide inhibitsangiogenesis.
   Google Scholar
• FRATER-SCHRODER M, RISAU W, HALLMAN R, GAUTSCHI P, BOHLEN P: Tumor necrosis factor type a, a potent in-hibitor of endothelial cell growth in vitro, is angio-genic in vivo. Proc. Natl. Acad. Sci. USA (1987) 84:5277–5281.
   PubMed Web of Science ®Google Scholar
• GUTMAN M, SZOLD A, RAVID AM et al.: Failure of tha-lidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. (1996) 16:3673–3678.
   PubMed Web of Science ®Google Scholar
• SMITH C, FRIEDNASH M, NGUYEN C, KNAUF T, WALSH P:Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model. J. Invest. Dermatol. (1996) 106:946. Abstract 845.
   Google Scholar
• KENYON BM, BROWNE F, D'AMATO RJ: Effects of tha-lidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64:971–978.
   PubMed Web of Science ®Google Scholar
• BAUER KS, DIXON SC, FIGG WD: Inhibition of angio-genesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. (1998) 55:1827–1834.
   PubMed Web of Science ®Google Scholar
• STIRLING D: Thalidomide and its impact in dermatol-ogy. Semin. Cutaneous Med. Surg. (1998) 17:231–242.
   PubMed Web of Science ®Google Scholar
• ••Current review of thalidomide's pharmacologic activity, ap-plications in dermatologic diseases and safety issues.
   Google Scholar
• SAYLAN T, SALTIK I: Thalidomide in the treatment of Behçet's syndrome. Arch. Dermatol (1982) 118:536.
   PubMed Web of Science ®Google Scholar
• GRINSPAN D: Significant response of oral aphthosis to thalidomide treatment. J. Am. Acad. Dermatol. (1985) 12:85–90.
   PubMed Web of Science ®Google Scholar
• MASCARO JM, LECHA M, TORRAS H et al.: Thalidomide in the treatment of recurrent, necrotic, and giant muco-cutaneous aphthae and aphthosis. Arch. Dermatol. (1979) 115:636–637.
   PubMed Web of Science ®Google Scholar
• BONNETBLANC JM, ROYER C, BEDANE C: Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology (1996) 193:321–323.
   PubMed Web of Science ®Google Scholar
• RADEFF B, KUFFER R, SAMSON J: Recurrent aphthous ul-cer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J. Am. Acad. Dermatol. (1990) 23:523–525.
   PubMed Web of Science ®Google Scholar
• NAUM SM, MOLLOY PJ, KANIA RJ, MCGARR J, VAN THIELDH: Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals. Dis. Sci. (1995) 40:1147–1148.
   PubMed Web of Science ®Google Scholar
• BALL SC, SEPKOWITZ KA, JACOBS JL: Thalidomide fortreatment of oral aphthous ulcers in patients with hu-man immunodeficiency virus: case report and review. Am. J. Gastroenterol. (1997) 92:169–170.
   PubMed Web of Science ®Google Scholar
• YOULE M, CLARBOUR J, FARTHING C et al.: Treatment ofresistant aphthous ulceration with thalidomide in pa-tients positive for HIV antibody. Br. Med. J. (1989) 298:432.
   PubMed Web of Science ®Google Scholar
• GHIGLIOTTI G, REPETTO T, FARRIS A, ROY MT, DE MAR-CHI R: Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunode-ficiency virus. J. Am. Acad. Dermatol (1993) 28:271–272.
   PubMed Web of Science ®Google Scholar
• DEVINCENZO JP, BURCHET SK: Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers. Pediatr. Infect. Dis. J. (1996) 15:465–467.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, GEORGHIOU PR, ALLWORTH AM, KEMPRJ: Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin. Infect. Dis. (1995) 20:250–254.
   PubMed Web of Science ®Google Scholar
• RYAN J, COLMAN J, PEDERSEN J, BENSON E: Thalido-mide to treat esophageal ulcer in AIDS. New Engl. J. Med. (1992) 327:208-209. Letter.
   Google Scholar
• MACREDMOND R, KEATING S, ARMSTRONG S, RYAN M,MULCAHY FM: The use of oral thalidomide in the treat-ment of oesophageal ulceration in AIDS. AIDS (1996) 10 (Suppl. 2):544. Abstract.
   Google Scholar
• JACOBSON JM, GREENSPAN JS, SPRITZLER J et al:Thalido-mide for the treatment of oral aphthous ulcers in pa-tients with human immunodeficiency virus infection. New Engl. J. Med. (1997) 336:1487–1493.
   PubMed Web of Science ®Google Scholar
• ••Large-scale controlled clinical trial.
   Google Scholar
• ALEXANDER LN, WILCOX CM: A prospective trial of tha-lidomide for the treatment of 'IN-associated idio-pathic esophageal ulcers. AIDS Res. Hum. Retroviruses (1997) 13:301–304.
   PubMed Web of Science ®Google Scholar
• GRUNFELD C, FEINGOLD KR: Metabolic disturbancesand wasting in the acquired immunodeficiency syn-drome. New Engl. J. Med. (1992) 327:329–337.
   PubMed Web of Science ®Google Scholar
• REYES-TERAN G, SIERRA-MADERO JG, MARTINEZ DEL CERRO V et al.: Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS (1996) 10:1501–1507.
   Google Scholar
• HASLETT P, HEMPSTEAD M, SEIDMAN C et al.: The meta-bolic and immunologic effects of short-term thalido-mide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retroviruses (1997) 13:1047–1054.
   PubMed Web of Science ®Google Scholar
• KAPLAN G, SCHAMBELAN M, GOTTLIEB M et al.: Thalido-mide reverses cachexia in HIV-wasting syndrome. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL (1998). Abstract 476.
   Google Scholar
• SHARPSTONE DR, ROWBOTTOM AW, LEPPER MW, NEL-SON MR, GAZZARD BG: Faecal tumour necrosis factor-a in individuals with HIV-related diarrhoea. AIDS (1996) 10:989–994.
   PubMed Web of Science ®Google Scholar
• SHARPSTONE D, ROWBOTTOM A, NELSON M, GAZZARDB: The treatment of microsporidial diarrhoea with tha-lidomide. AIDS (1995) 9:658–659.
   PubMed Web of Science ®Google Scholar
• QUINONES F, SIERRA-MADERO J, CALVA-MERCADO JJ,RUIZ-PALACIOS GM: Thalidomide in patients with HIV infection and chronic diarrhea: double blind placebo controlled clinical trial. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC (1997). Ab-stract 682.
   Google Scholar
• SHARPSTONE D, ROWBOTTOM A, FRANCIS N et al.: Tha-lidomide: a novel therapy for microsporidiosis. Gas-troenterology (1997) 112:1823–1829.
   PubMed Web of Science ®Google Scholar
• GUNZLER V: Thalidomide in human immunodefi-ciency virus (HIV) patients. DrugSafety (1992) 7:116–134.
   Google Scholar
• SAURAT J-H, CAMENZIND M, HELG C, CHAPUIS B: Tha-lidomide for graft-versus-host disease after bone mar-row transplantation. Lancet (1988) 1:359. Letter.
   Google Scholar
• LIM SH, MCWHANNELL A, VORA AJ, BOUGHTON BJ: Suc-cessful treatment with thalidomide of acute graft- ver-sus-host disease after bone-marrow transplantation. Lancet (1988) 1:117. Letter.
   Google Scholar
• HENEY D, NORFOLK DR, WHEELDON J et al.: Thalido-mide treatment for chronic graft-versus-host disease. Br. J. Haematol (1991) 78:23–27.
   PubMed Web of Science ®Google Scholar
• VOGELSANG GB, FARMER ER, HESS AD et al: Thalido-mide for the treatment of chronic graft-versus-host disease. New Engl. J. Med. (1992) 326:1055–1058.
   PubMed Web of Science ®Google Scholar
• WOOD PMD, PROCTOR SJ: The potential use of thalido-mide in the therapy of graft-versus-host disease - a re-view of clinical and laboratory information. Leuk. Res. (1990) 14:395–399.
   PubMed Web of Science ®Google Scholar
• JORIZZO JL, SCHMALSTIEG FC, SOLOMON AR et al.: Tha-lidomide effects in Behçet's syndrome and pustular vasculitis. Arch. Intern. Med. (1986) 146:878–881.
   PubMed Web of Science ®Google Scholar
• HAMZA M: Behçet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide. Clin. Exp. Rheumatol. (1990) 8:427.
   PubMed Web of Science ®Google Scholar
• HAMURYUDAN V, MAT C, SAIP S et al: Thalidomide inthe treatment of the mucocutaneous lesions of Behçet's syndrome: a randomized, double-blind, pla-cebo controlled trial. Ann. Intern. Med. (1998) 128:443–450.
   PubMed Web of Science ®Google Scholar
• LO JS, BERG RE, TOMECKI KJ: Treatment of discoid lu-pus erythematosus. Int. j Dermatol. (1989) 28:497–507.
   PubMed Web of Science ®Google Scholar
• KNOP J, BONSMANN G, HAPPLE R et al.: Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br. J. Dermatol. (1983) 108:461–466.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ-RODRIGUEZ O: Thalidomide: a promisingnew treatment for rheumatoid arthritis. Arthritis Rheum. (1984) 27:1118–1121.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ-RODRIGUEZ O, STARUSTA-BACAL P, GUTIERREZ-MONTES O: Treatment of rheumatoid ar-thritis - the thalidomide experience. J. Rheumatol (1989) 16:158–163.
   PubMed Web of Science ®Google Scholar
• HUIZINGA TWJ, DIJKMANS BAC, VAN DER VELDE EA etal.: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid ar-thritis. Ann. Rheum. Dis. (1996) 55:833–836.
   PubMedGoogle Scholar
• MCGEEHAN GM, UHL J: TNF-a in human diseases. Curr.Pharm. Des. (1996) 2:662–667.
   Web of Science ®Google Scholar
• KAPLAN G, FREEDMAN VH: The role of cytokines in theimmune response to tuberculosis. Res. Immunol. (1996) 147:565–572.
   PubMedGoogle Scholar
• KAPLAN G, MOREIRA AL: TNFa regulation of HIV1: biol-ogy and therapy. Res. Immunol. (1994) 145:685–689.
   PubMedGoogle Scholar
• MAKONKAWKEYOON S, LIMSON-POBRE RNR, MOREIRAAL, SCHAUF V, KAPLAN G: Thalidomide inhibits the rep-lication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1993) 90:5974–5978.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, CORRAL LG, YE W et al.: Thalidomide andthalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res. Hum. Retrovi-ruses (1997) 13:857–863.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA JM, UTAIPAT U, MOLLOY A eta].: Thalido-mide treatment reduces tumor necrosis factor a pro-duction and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. (1995) 1:384–397.
   Google Scholar
• KAPLAN G: Thalidomide treatment reduces TNF-a al-pha production and enhances weight gain in patients with pulmonary tuberculosis. J. Cell. Biochem. (1995) 57 (Suppl. 19B):61. Abstract.
   Google Scholar
• SCHMIDT H, RUSH B, SIMONIAN G etal.: Thalidomide in-hibits TNF response and increases survival following endotoxin injection in rats. J. Surg. Res. (1996) 63:143–146.
   Google Scholar
• NETEA MG, BLOK WL, KULLBERG BJ et al: Pharma-cologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infections with live microorganisms in mice. J. Infect. Dis. (1995) 171:393–399.
   PubMed Web of Science ®Google Scholar
• ZWINGENBERGER K, WNENDT S: Immunomodulationby thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. (1996) 46:177–211.
   Google Scholar
• MOREIRA AL, WANG J, SARNO EN, KAPLAN G: Thalido-mide protects mice against LPS-induced shock. Braz. J. Med. Biol. Res. (1997) 30:1199–1207.
   PubMed Web of Science ®Google Scholar
• HENDEL J, BRYNSKOV J, SAERMARK T, BENDTZEN K: Ex-perimental cytokine modulation therapy of inflamma-tory bowel disease (Crohn's disease and ulcerative colitis). Exp. Opin. Invest. Drugs (1996) 5:843–850.
   Google Scholar
• WATERS MFR, LAING ABG, AMBIKAPATHY A, LENNARD-JONES JE: Treatment of ulcerative colitis with thalido-mide. Br. Med. J. (1979) 1(6166):792.
   PubMed Web of Science ®Google Scholar
• ZHU J, BAT X, MIX E et al.: Thalidomide suppresses T-and B-cell responses to myelin antigen in experimen-tal allergic neuritis. Clin. NeuropharmacoL (1997) 20:152–162.
   PubMed Web of Science ®Google Scholar
• MARTINO G, CONSIGLIO A, FRANCIOTTA DM et al.: Tu-mor necrosis factor a and its receptors in relapsing-remitting multiple sclerosis. J. NeuroL Sci. (1997) 152:51–61.
   PubMed Web of Science ®Google Scholar
• PHILIPPE J, DEBRUYNE J, LEROUX-ROELS G, WILLEMS A,DEREUCK J: In vitro TNF-a, 11-2, and IFNI production as markers of relapses in multiple sclerosis. Clin. Neu-rol Neurosurg. (1996) 98:286–290.
   PubMed Web of Science ®Google Scholar
• SELMAJ K, PAPIERZ W, GLABINSKI A, KOHNO T: Preven-tion of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor 1.1 Neuroimmunol. (1995) 56:135–141.
   Google Scholar
• BURROUGHS MH, TSENOVA-BERKOVA L, SOKOL K et al:Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial menin-gitis. Microb. Pathog. (1995) 19:245–255.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, CERAMI A: Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann. Rev. Biochem. (1988) 57:505.
   PubMed Web of Science ®Google Scholar
• ARGILES JM, LOPEZ-SORIANO FJ: Cancer cachexia: a key role for TNF? Int. J. Oncol (1997) 10:562–572.
   Google Scholar
• OLIFF A, DEFEO-JONES D, BOYER M et al.: Tumors se-creting human TNF/cachectin induce cachexia in mice. Cell (1987) 50:555–563.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, MORGELLO S, KOPLIN B et al.: Metabolic ef-fects of cachectin/tumor necrosis factor are modified by site of production: cachectin/tumor necrosis factor in skeletal muscle induces chronic cachexia, while im-plantation in brain induces predominantly acute ano-rexia. J. Clin. Invest. (1990) 86:2014–2024.
   PubMed Web of Science ®Google Scholar
• GARCIA-MARTINEZ C, COSTELLI P, LOPEZ-SORIANO FJ, ARGILES JM: Is TNF really involved in cachexia? Investi-gation (1997) 15:47–54.
   PubMed Web of Science ®Google Scholar
• BALOG DL, EPSTEIN ME, AMODIO-GROTON MI: HIV wasting: treatment update. Ann. Pharmacother. (1998) 32:446–458.
   PubMed Web of Science ®Google Scholar
• GRABSTALD H, GOLBEY R: Clinical experiences withthalidomide in patients with cancer. Clin. Pharmacol. Ther. (1965) 6:298–302.
   PubMed Web of Science ®Google Scholar
• OLSON KB, HALL TC, HORTON J, KHUNG CL, HOSLEY HF:Thalidomide (./V-phthaloylglutamide) in the treatment of advanced cancer. Clin. PharmacoL Ther. (1965) 6:292–297.
   PubMed Web of Science ®Google Scholar
• EUROPEAN BREAST CANCER GROUP: Clinical trial of thecyclic imide 1- (morpholinomethyl)-4-phtalimido-piperidindione-2,6 (CG 603) in advanced breast cancer. Eur. J. Cancer (1972) 8:157–158.
   PubMed Web of Science ®Google Scholar
• SOLER RA, HOWARD M, BRINK NS et al.: Regression ofAIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin. Infect. Dis. (1996) 23:501–503.
   PubMed Web of Science ®Google Scholar
• WELLES L, LITTLER, WYVILL K et al.: Preliminary results of Phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS). J. Acquir. Im-mune Defic. Synd. Hum. Retrovirol. (1997) 14:A21. Abstract
   Google Scholar
• BOWER M, HOWARD M, GRACIE F, PHILLIPS R, FIFE K: A Phase II study of thalidomide for Kaposi's sarcoma: ac-tivity and correlation with KSHV DNA load. J. Acquir. Immune Defic. Synd. Hum. Retrovirol. (1997) 14:A35. Ab-stract 76.
   Google Scholar
• MINCHINTON Al, FRYER KH, WENDT KR, CLOW KA, HAYES MMM: The effect of thalidomide on experimen-tal tumors and metastases. Anticancer Drugs (1996) 7:339–343.
   PubMed Web of Science ®Google Scholar
• NGUYEN M, TRAN C, BARSKY S et al: Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int. J. Oncol (1997) 10:965–969.
   PubMed Web of Science ®Google Scholar
• CHING L-M, XU Z-F, GUMMER BH et al: Effect of thalido-mide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer (1995) 72:339–343.
   PubMed Web of Science ®Google Scholar
• LONG G, VREDENBURGH J, RIZZIERI DA et al: Pilot trial of thalidomide post-autologous peripheral blood pro-genitor cell transplantation PBPC in patients with metastatic breast cancer. Proc. ASCO (1998) 17:181a. Ab-stract 697.
   Google Scholar
• EISEN T, BOSHOFF C, VAUGHAN MM et al.: Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: a Phase II study. Proc. ASCO (1998) 17:441a. Abstract 1699.
   Google Scholar
• FIGG WD, BERGAN R, BRAWLEY O et al.: Randomized Phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc. ASCO (1998) 17:333a. Abstract 1189.
   Google Scholar
• FINE HA, LOEFFLER JS, KYRITSIS N et al.: A Phase II trial of the antiangiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc. ASCO (1998) 17:385a. Abstract 1372.
   Google Scholar
• NEUBERT R, NEUBERT D: Peculiarities and possible mode of action of thalidomide. In:Drug Toxicity in Em-bryonic Development. Kavlock, Daston (Eds.). In: Hand-book of Experimental Pharmacology. Born, GVR, Cuatrecasas P, Ganten D, Herken H. Melmon KL (Eds.), Springer Verlag (1996) 124.2:41–120.
   Google Scholar
• •This review covers the possible mechanisms of thalido-mide's teratogenic potential, and covers the clinical recogni-tion and investigation of the teratogenicity.
   Google Scholar
• LENZ VW, KNAPP K: Die Thalidomid-Embryopathie. Dtsch. Med. Wochenschr. (1962) 87:1232–1242.
   PubMed Web of Science ®Google Scholar
• STEPHENS TD: Proposed mechanisms of action in tha-lidomide embryopathy. Teratology (1988) 38:229–239.
   PubMedGoogle Scholar
• POWELL RJ, GARDNER-MEDWIN JMM: Guideline for the clinical use and dispensing of thalidomide. Postgrad. Med. J. (1994) 70:901–904.
   PubMed Web of Science ®Google Scholar
• •Important for those considering use of thalidomide therapy.
   Google Scholar
• MITCHELL AA, VAN BENNEKOM CM, LOUIK C: A pregnancy-prevention program in women of child-bearing age receiving isotretinoin. New Engl. J. Med. (1995) 333:101–106.
   PubMed Web of Science ®Google Scholar
• AMELUNG W, PUNTMANN E: Clinical and therapeutical aspects of `Contegan-induced polyneuropathy'. Der Nervenartz (1966) 37 (5) :189–199.
   PubMedGoogle Scholar
• OCHONISKY S, VERROUST J, BASTUJI-GARIN S, GHER-ARDI R, REVUZ J: Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch. Dermatof (1994) 130:66–69.
   PubMed Web of Science ®Google Scholar
• •Discussion of the incidence of thalidomide-associated neu-ropathy and the relationship to dosing in patients treated for various dermatologic diseases.
   Google Scholar
• FULLERTON PM, O'SULLIVAN DJ: Thalidomide neuropa-thy: a clinical, electrophysiological, and histological follow-up study. J. Neurol. Neurosurg. Psychiat. (1968) 31:543–551.
   PubMed Web of Science ®Google Scholar
• GARDNER-MED WINJMM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of se-vere oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53:828–832.
   PubMed Web of Science ®Google Scholar
• GROSSHANS E, ILLY G: Thalidomide therapy for inflam-matory dermatoses. Int. J. Dermatol. (1984) 23:598–602.
   PubMed Web of Science ®Google Scholar